Novo Nordisk Receives FDA Approval of Saxenda Label Update
The FDA has approved an updated product label for Saxenda (liraglutide) injection 3 mg.
The updated label includes clinical trial data supporting the safety and efficacy of the drug over a 3-year term.
Approximately half of patients on Saxenda who lost more than or equal to 5 percent of their weight after 56 weeks, maintained their weight loss for 3 years.
The drug may help some adults with excess weight who also have weight-related medical problems or obesity lose weight and keep the weight off.
Saxenda was approved by the FDA in December 2014.